Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.

ABSTRACT:

Background

Although Zika virus (ZIKV) infection is typically self-limiting, other associated complications such as congenital birth defects and the Guillain-Barré syndrome are well described. There are no approved vaccines against ZIKV infection.

Methods

In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each. The participants received either 1 mg or 2 mg of vaccine intradermally, with each injection followed by electroporation (the use of a pulsed electric field to introduce the DNA sequence into cells) at baseline, 4 weeks, and 12 weeks.

Results

The median age of the participants was 38 years, and 6

SUBMITTER: Tebas P 

PROVIDER: S-EPMC6824915 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature